Chung-Han Lee, MD, PhD, on TKI/IO Combination Therapy for Non–Clear Cell RCC

Video

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

CancerNetwork® sat down with Chung-Han Lee, MD, PhD, from Memorial Sloan Kettering Cancer Center, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about potential implications of using frontline pembrolizumab (Keytruda) and lenvatinib (Lenvima) for non–clear cell renal cell carcinoma (RCC), which will be examined in the phase 2 KEYNOTE-B61 trial (NCT04704219) that is currently recruiting patients. He discussed how patients respond to immune check point inhibitors and what benefits they could see from using this specific combination.

Transcription:

What we already know about the non­–clear cell [RCC] space is that pembrolizumab is a very active agent. However, not everyone responds [with] the addition of an a tyrosine kinase inhibitor to an immune checkpoint inhibitor. We do hope to see continued responses. I think one of the key questions that we hope to answer eventually, is whether or not they’re distinct subpopulations that particularly benefit from this type of combination, and also whether or not these 2 compounds interact with each other in such a way that provides synergism.

Reference

Chung-Han L, Chenxiag L, Rodolfo PF, et al. Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol. 39;2021(suppl 15):TPS4595. doi:10.1200/JCO.2021.39.15_suppl.TPS4595

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content